Relmada Therapeutics, Inc. (RLMD) Research

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.

Market snapshot

Symbol
RLMD
Price
$6.73
Day change
+1.97%
Market cap
$493.5M
P/E ratio
-9.90x
52-week range
0.52-8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.75

Recent news

  • Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

    On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen.

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Cibus, Inc. (CBUS)
  • Fortress Biotech, Inc. (FBIO)
  • Immunic, Inc. (IMUX)
  • Lite Strategy, Inc. (LITS)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • Repare Therapeutics Inc. (RPTX)

Recent insider activity

  • TRAVERSA SERGIO — P-Purchase (27500 shares) on 2025-12-15
  • TRAVERSA SERGIO — A-Award (1198000 shares) on 2025-12-12
  • Shenouda Maged — A-Award (828000 shares) on 2025-12-12
  • Shenouda Maged — P-Purchase (11665 shares) on 2025-12-15
  • Ence Chuck — A-Award (828000 shares) on 2025-12-12

Open Relmada Therapeutics, Inc. (RLMD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.